中国医院用药评价与分析Issue(7)：606-608,609,4.
南京地区33家医院2010-2012年分子靶向抗肿瘤药利用分析
Utilization of Molecular Targeted Anti-tumor Drugs in 33 Hospitals of Nanjing City from 2010 to 2012
摘要
Abstract
OBJECTIVE:To evaluate the clinical utilization of molecular targeted anti-tumor drugs in Nanjing city. METH-ODS:The utilization of molecular targeted anti-tumor drugs in 33 hospitals of Nanjing city during 2010-2012 period was analyzed statistically with regard to consumption sum and DDDs. RESULTS:The consumption sum and DDDs of molecular targeted drugs in Nanjing city increased year by year,with annual growth rate of 35.39% and 18.56%,respectively. From 2010 to 2012,the top four drugs in consumption sum were rituximab,recombinant human endostatin,trastuzumab and gefitinib;the top three drugs in DDDs were gefitinib,recombinant human endostatin and erlotinib;the top three manufacturers ranked by sales amount were Roche Pharmaceuticals Co. Ltd.,Shandong Simcere-Medgenn Bio-pharmaceutical Co. Ltd. and Astrazeneca Trading Co. Ltd. CONCLU-SIONS:The consumption of molecular targeted anti-tumor drugs in Nanjing city shows an upward trend from 2010 to 2012,indi-cating the increasing popularity of molecular targeted drugs.关键词
分子靶向药物/抗肿瘤药/用药频度/南京地区Key words
Molecular targeted drug/Anti-tumor drug/DDDs/Nanjing city分类
医药卫生引用本文复制引用
李想,戴惠珍,陶琳,孟玲..南京地区33家医院2010-2012年分子靶向抗肿瘤药利用分析[J].中国医院用药评价与分析,2014,(7):606-608,609,4.基金项目
江苏高校优势学科建设工程资助项目 （）
